Sign in
Taking people in PolandPhase 1

Continues OATD-02 treatment for people with advanced solid tumours

Tests OATD-02 in adults with advanced colorectal, ovarian, pancreatic or kidney cancer.

Key facts

Who runs it
Molecure S.A.
Where
Bydgoszcz, Otwock, and Warsaw, PolandSee the 3 sites
Registry title
An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/or metastatic solid tumours who completed the first-in-human study OATD-02-C-01
Status
Recruiting
Phase
Phase 1
People taking part
30 people, planned
Started
23 Aug 2023
Expected to end
7 Mar 2028
Type of study
Interventional
Record updated
19 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic colorectal, ovarian, pancreatic or renal cell cancer who completed the first-in-human study OATD-02-C-01.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced and/or metastatic solid tumours: colorectal cancer, ovarian cancer, pancreatic cancer or renal cell carcinoma.
Earlier treatment
Must have completed the first-in-human study OATD-02-C-01.

Where in Poland

  • Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W BydgoszczyBydgoszcz, PolandTaking people
  • Europejskie Centrum Zdrowia Otwock Sp. Z.o.o.Otwock, PolandTaking people
  • LUX MED Onkologia Sp. z.o.o.Warsaw, PolandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Continues OATD-02 treatment for people with advanced solid tumoursGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
19 February 2026